These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 32855439)

  • 1. Anti-SARS-CoV-2 antibody response in patients with chronic lymphocytic leukemia.
    Roeker LE; Knorr DA; Pessin MS; Ramanathan LV; Thompson MC; Leslie LA; Zelenetz AD; Mato AR
    Leukemia; 2020 Nov; 34(11):3047-3049. PubMed ID: 32855439
    [No Abstract]   [Full Text] [Related]  

  • 2. Recovered COVID-19 patients with recurrent viral RNA exhibit lower levels of anti-RBD antibodies.
    Liu B; Shi Y; Zhang W; Li R; He Z; Yang X; Pan Y; Deng X; Tan M; Zhao L; Zou F; Zhang Y; Pan T; Zhang J; Zhang X; Xiao F; Li F; Deng K; Zhang H
    Cell Mol Immunol; 2020 Oct; 17(10):1098-1100. PubMed ID: 32939033
    [No Abstract]   [Full Text] [Related]  

  • 3. Mining of epitopes on spike protein of SARS-CoV-2 from COVID-19 patients.
    Zhang BZ; Hu YF; Chen LL; Yau T; Tong YG; Hu JC; Cai JP; Chan KH; Dou Y; Deng J; Wang XL; Hung IF; To KK; Yuen KY; Huang JD
    Cell Res; 2020 Aug; 30(8):702-704. PubMed ID: 32612199
    [No Abstract]   [Full Text] [Related]  

  • 4. Duration of serum neutralizing antibodies for SARS-CoV-2: Lessons from SARS-CoV infection.
    Lin Q; Zhu L; Ni Z; Meng H; You L
    J Microbiol Immunol Infect; 2020 Oct; 53(5):821-822. PubMed ID: 32249185
    [No Abstract]   [Full Text] [Related]  

  • 5. A COVID-19 Patient with Repeatedly Undetectable SARS-CoV-2 Antibodies.
    Goetz L; Yang J; Greene W; Zhu Y
    J Appl Lab Med; 2020 Nov; 5(6):1401-1405. PubMed ID: 32745181
    [No Abstract]   [Full Text] [Related]  

  • 6. Expansion of SARS-CoV-2-Specific Antibody-Secreting Cells and Generation of Neutralizing Antibodies in Hospitalized COVID-19 Patients.
    Varnaitė R; García M; Glans H; Maleki KT; Sandberg JT; Tynell J; Christ W; Lagerqvist N; Asgeirsson H; Ljunggren HG; Ahlén G; Frelin L; Sällberg M; Blom K; Klingström J; Gredmark-Russ S
    J Immunol; 2020 Nov; 205(9):2437-2446. PubMed ID: 32878912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluations of the serological test in the diagnosis of 2019 novel coronavirus (SARS-CoV-2) infections during the COVID-19 outbreak.
    Lin D; Liu L; Zhang M; Hu Y; Yang Q; Guo J; Dai Y; Xu Y; Cai Y; Chen X; Huang K; Zhang Z
    Eur J Clin Microbiol Infect Dis; 2020 Dec; 39(12):2271-2277. PubMed ID: 32681308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Orthogonal SARS-CoV-2 Serological Assays Enable Surveillance of Low-Prevalence Communities and Reveal Durable Humoral Immunity.
    Ripperger TJ; Uhrlaub JL; Watanabe M; Wong R; Castaneda Y; Pizzato HA; Thompson MR; Bradshaw C; Weinkauf CC; Bime C; Erickson HL; Knox K; Bixby B; Parthasarathy S; Chaudhary S; Natt B; Cristan E; El Aini T; Rischard F; Campion J; Chopra M; Insel M; Sam A; Knepler JL; Capaldi AP; Spier CM; Dake MD; Edwards T; Kaplan ME; Scott SJ; Hypes C; Mosier J; Harris DT; LaFleur BJ; Sprissler R; Nikolich-Žugich J; Bhattacharya D
    Immunity; 2020 Nov; 53(5):925-933.e4. PubMed ID: 33129373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kinetic changes in virology, specific antibody response and imaging during the clinical course of COVID-19: a descriptive study.
    Wang QJ; Yao YZ; Song JS; Wang Q; Xu LY; Bao ZJ; Mao DW; Zhou JH; Zhang ZE; Wang Y; Li YW; Wang HP; Li L; Pan HY; Zhang GQ; Li SB
    BMC Infect Dis; 2020 Nov; 20(1):818. PubMed ID: 33167900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinct Early Serological Signatures Track with SARS-CoV-2 Survival.
    Atyeo C; Fischinger S; Zohar T; Slein MD; Burke J; Loos C; McCulloch DJ; Newman KL; Wolf C; Yu J; Shuey K; Feldman J; Hauser BM; Caradonna T; Schmidt AG; Suscovich TJ; Linde C; Cai Y; Barouch D; Ryan ET; Charles RC; Lauffenburger D; Chu H; Alter G
    Immunity; 2020 Sep; 53(3):524-532.e4. PubMed ID: 32783920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low prevalence of IgG antibodies to SARS-CoV-2 in cancer patients with COVID-19.
    Liu T; Zeng G; Tao H; Shi Y; ; Wang T; Liu T; Guo F; Zhou F; Wang X
    Int J Cancer; 2020 Dec; 147(11):3267-3269. PubMed ID: 32525566
    [No Abstract]   [Full Text] [Related]  

  • 12. Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack Rate.
    Addetia A; Crawford KHD; Dingens A; Zhu H; Roychoudhury P; Huang ML; Jerome KR; Bloom JD; Greninger AL
    J Clin Microbiol; 2020 Oct; 58(11):. PubMed ID: 32826322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistent COVID-19 Pneumonia and Failure to Develop Anti-SARS-CoV-2 Antibodies During Rituximab Maintenance Therapy for Follicular Lymphoma.
    Yasuda H; Tsukune Y; Watanabe N; Sugimoto K; Uchimura A; Tateyama M; Miyashita Y; Ochi Y; Komatsu N
    Clin Lymphoma Myeloma Leuk; 2020 Nov; 20(11):774-776. PubMed ID: 32933879
    [No Abstract]   [Full Text] [Related]  

  • 14. Serum-IgG responses to SARS-CoV-2 after mild and severe COVID-19 infection and analysis of IgG non-responders.
    Marklund E; Leach S; Axelsson H; Nyström K; Norder H; Bemark M; Angeletti D; Lundgren A; Nilsson S; Andersson LM; Yilmaz A; Lindh M; Liljeqvist JÅ; Gisslén M
    PLoS One; 2020; 15(10):e0241104. PubMed ID: 33085715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cellular immune responses to covid-19.
    Sewell HF; Agius RM; Stewart M; Kendrick D
    BMJ; 2020 Jul; 370():m3018. PubMed ID: 32737031
    [No Abstract]   [Full Text] [Related]  

  • 16. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2.
    Chi X; Yan R; Zhang J; Zhang G; Zhang Y; Hao M; Zhang Z; Fan P; Dong Y; Yang Y; Chen Z; Guo Y; Zhang J; Li Y; Song X; Chen Y; Xia L; Fu L; Hou L; Xu J; Yu C; Li J; Zhou Q; Chen W
    Science; 2020 Aug; 369(6504):650-655. PubMed ID: 32571838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sensitivity in Detection of Antibodies to Nucleocapsid and Spike Proteins of Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Coronavirus Disease 2019.
    Burbelo PD; Riedo FX; Morishima C; Rawlings S; Smith D; Das S; Strich JR; Chertow DS; Davey RT; Cohen JI
    J Infect Dis; 2020 Jun; 222(2):206-213. PubMed ID: 32427334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accurate serology for SARS-CoV-2 and common human coronaviruses using a multiplex approach.
    van Tol S; Mögling R; Li W; Godeke GJ; Swart A; Bergmans B; Brandenburg A; Kremer K; Murk JL; van Beek J; Wintermans B; Reimerink J; Bosch BJ; Reusken C
    Emerg Microbes Infect; 2020 Dec; 9(1):1965-1973. PubMed ID: 32819220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutralizing antibody responses to SARS-CoV-2 in COVID-19 patients.
    Deshpande GR; Sapkal GN; Tilekar BN; Yadav PD; Gurav Y; Gaikwad S; Kaushal H; Deshpande KS; Kaduskar O; Sarkale P; Baradkar S; Suryawanshi A; Lakra R; Sugunan AP; Balakrishnan A; Abraham P; Salve P
    Indian J Med Res; 2020 Jul & Aug; 152(1 & 2):82-87. PubMed ID: 32859866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody Responses to SARS-CoV-2 at 8 Weeks Postinfection in Asymptomatic Patients.
    Choe PG; Kang CK; Suh HJ; Jung J; Kang E; Lee SY; Song KH; Kim HB; Kim NJ; Park WB; Kim ES; Oh MD
    Emerg Infect Dis; 2020 Oct; 26(10):2484-2487. PubMed ID: 32579877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.